

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

NMPA Approval for Registration Application of Syphonet® Stent Retriever

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on February 11, 2022, the Group received the approval from the National Medical Products Administration (國家藥品監督管理局)(the “**NMPA**”) for the registration application of Syphonet® Stent Retriever (formerly named as Shenyi® in English), making it the Group’s eleventh NMPA approved neurointerventional product.

The Syphonet® Stent Retriever is a technologically advanced product developed by Achieva Medical Limited (“**Achieva**”), a wholly-owned subsidiary of the Company, through our persistent dedication to innovation and clear understanding of clinical needs. The product’s unique design features a capture basket at the distal end, which can effectively prevent the thrombus fragments from dislodging into the blood stream, thereby improving the removal of the thrombus. The stent is also designed with optimized radial force to maintain the integrity of the lumen even in curved vessels. Radiopaque wires in the stent and a radiopaque marker on the distal end allow for a fluoroscopic visualization of the entire retriever, facilitating physicians with better visual guidance. The Syphonet® Stent Retriever has various specifications, all compatible with 0.017-inch micro-catheter. The compatibility feature will improve the success rate of deployment and reduce procedure time.

The registration approval of the Syphonet® Stent Retriever marks the further expansion of Achieva's product portfolio for ischemic stroke treatment, which will now include the Syphonet® Stent Retriever, Tethys® Intermediate Catheter, Presgo® Micro Guidewire and Presgo® Micro Catheter. With the successive launch of Tethys AS® Aspiration Catheter and Fluxcap® Balloon Guiding Catheter this year, Achieva will be able to provide physicians a fully integrated solution for mechanical thrombectomy. Physicians can rely on Achieva's product combinations for different procedures, based on the clinical manifestations of patients.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET Syphonet® STENT RETRIEVER SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, February 16, 2022

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip, and Mr. Huacheng Wei as independent non-executive Directors.